AstraZeneca Reports Imfinzi (durvalumab) & tremelimumab Results in P-III EAGLE trial for Advanced Head and Neck Cancer
AstraZeneca Reports Imfinzi (durvalumab) & tremelimumab Results in P-III EAGLE trial for Advanced Head and Neck Cancer
Shots:
- The P-III EAGLE study involved assessing of Imfinzi as monothx or Imfinzi + tremelimumab vs SoC CT in patients with recurrent or metastatic HNSCC who experienced progression following Pt-based CT, at 169 centers across 24 countries
- The P-III EAGLE study results demonstrated that it didn’t met 1EPs as OS and has shown safety and well-tolerated signs in patients
- Imfinzi (durvalumab) is a mAb, binds with PD-L1 and blocks its interaction with PD-1 and CD80, is approved in 40 countries including the US, EU and Japan for Stage III NSCLC. Tremelimumab is a mAb, used for targeting the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
Click here to read full press release/ article | Ref: AstraZeneca | Image Source: DW